会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明申请
    • Novel heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity
    • 新型杂环取代吡啶或具有CXCR3拮抗活性的苯基化合物
    • US20060217392A1
    • 2006-09-28
    • US11353609
    • 2006-02-14
    • Gopinadhan AnilkumarQingbei ZengStuart RosenblumJoseph KozlowskiBrian McGuinnessDouglas Hobbs
    • Gopinadhan AnilkumarQingbei ZengStuart RosenblumJoseph KozlowskiBrian McGuinnessDouglas Hobbs
    • C07D403/14A61K31/496
    • C07D417/14C07D401/04C07D401/14C07D413/14
    • The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prod rug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, zenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.
    • 本申请公开了所述化合物或所述前药的所述化合物或其药学上可接受的盐,溶剂合物或酯的化合物或对映异构体,立体异构体,旋转异构体,互变异构体,产物,所述化合物具有式 1:或其药学上可接受的盐,溶剂化物或酯。 还公开了治疗趋化因子介导的疾病的方法,例如姑息治疗,疗效治疗,某些疾病和疾病如炎性疾病的预防性治疗(非限制性实例,牛皮癣),自身免疫性疾病(非限制性的 例如,类风湿性关节炎,多发性硬化),移植物排斥(非限制性实例,包括同种异体移植排斥,移植排斥),感染性疾病(例如结核性麻风病),固定药物喷发,皮肤迟发型超敏反应 应答,眼部炎症,I型糖尿病,病毒性脑膜炎和使用式1的化合物的肿瘤。
    • 9. 发明申请
    • Piperazine-piperidines with CXCR3 antagonist activity
    • 哌嗪 - 哌啶与CXCR3拮抗剂活性
    • US20060276457A1
    • 2006-12-07
    • US11353806
    • 2006-02-14
    • Wensheng YuSeong KimGopinadhan AnilkumarStuart RosenblumBandarpalle ShankarBrian McGuinnessDouglas HobbsYuefei Shao
    • Wensheng YuSeong KimGopinadhan AnilkumarStuart RosenblumBandarpalle ShankarBrian McGuinnessDouglas HobbsYuefei Shao
    • A61K31/551A61K31/498A61K31/496A61K31/525C07D487/02C07D475/02
    • C07D487/04C07D401/12
    • The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.
    • 本申请公开了所述化合物或所述前体药物的所述化合物或其药学上可接受的盐,溶剂合物或酯的化合物或对映异构体,立体异构体,旋转异构体,互变异构体或前药,所述化合物具有式1所示的一般结构 :或其药学上可接受的盐,溶剂合物或酯,其中各种部分在本文中定义。 还公开了治疗趋化因子介导的疾病的方法,例如姑息治疗,疗效治疗,某些疾病和疾病如炎性疾病的预防性治疗(非限制性实例,牛皮癣),自身免疫性疾病(非限制性的 例如,类风湿性关节炎,多发性硬化症),移植排斥反应(非限制性实例包括,同种异体移植排斥反应,异种移植物排斥),感染性疾病(例如结核性麻风病),固定药物爆发,皮肤迟发型超敏反应 应答,眼部炎症,I型糖尿病,病毒性脑膜炎和使用式1的化合物的肿瘤。
    • 10. 发明申请
    • Substituted heterocyclic compounds with CXCR3 antagonist activity
    • 取代的具有CXCR3拮抗剂活性的杂环化合物
    • US20070082913A1
    • 2007-04-12
    • US11545201
    • 2006-10-10
    • Seong KimBandarpalle ShankarJoseph KozlowskiStuart RosenblumNeng-Yang Shih
    • Seong KimBandarpalle ShankarJoseph KozlowskiStuart RosenblumNeng-Yang Shih
    • A61K31/497A61K31/496C07D403/14
    • C07D401/14C07D401/08C07D413/14
    • The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, type I diabetes, viral meningitis and tumors using a compound of Formula 1.
    • 本申请公开了所述化合物或所述前体药物的所述化合物或其药学上可接受的盐,溶剂合物或酯的化合物或对映异构体,立体异构体,旋转异构体,互变异构体或前药,所述化合物具有式1所示的一般结构 :或其药学上可接受的盐,溶剂合物或酯,其中各种部分在本文中定义。 还公开了治疗趋化因子介导的疾病的方法,例如姑息治疗,疗效治疗,某些疾病和疾病如炎性疾病的预防性治疗(非限制性实例,牛皮癣),自身免疫性疾病(非限制性的 例如,类风湿性关节炎,多发性硬化症),移植排斥反应(非限制性实例包括,同种异体移植排斥反应,异种移植物排斥),感染性疾病(例如结核性麻风病),固定药物爆发,皮肤迟发型超敏反应 应答,I型糖尿病,病毒性脑膜炎和使用式1的化合物的肿瘤。